| Higgins PJ, Ko JL, Lobell R, Sardonini C, Alessi MK, Yeh CG |
------>authors3_c=None ------>paper_class1=1 ------>Impact_Factor=None ------>paper_class3=2 ------>paper_class2=1 ------>vol=158 ------>confirm_bywho=microbes ------>insert_bywho=jonko ------>Jurnal_Rank=None ------>authors4_c=None ------>comm_author= ------>patent_EDate=None ------>authors5_c=None ------>publish_day=None ------>paper_class2Letter=None ------>page2=2881 ------>medlineContent= ------>unit=E0104 ------>insert_date=20031016 ------>iam=2 ------>update_date= ------>author=??? ------>change_event=5 ------>ISSN=None ------>authors_c=None ------>score=500 ------>journal_name=Journal of Immunology ------>paper_name=A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities ------>confirm_date=20031017 ------>tch_id=092070 ------>pmid=9058824 ------>page1=2872 ------>fullAbstract=A chimeric gene was constructed from the genes coding for the human complement regulatory proteins, membrane cofactor protein (CD46) and decay-accelerating factor (CD55). The recombinant chimeric gene was transfected into Chinese hamster ovary cells. The gene product is a soluble, glycosylated, 110-kDa protein named complement activation blocker-2 (CAB-2). This protein possesses both factor I cofactor activity and decay-accelerating activity, and inactivates classical and alternative C3/C5 convertases in vitro. The specific activity of CAB-2 against cell-associated convertases is greater than that of soluble forms of either membrane cofactor protein or decay-accelerating factor or of both factors combined. CAB-2 also blocks the activation of complement in vivo, inhibiting both the Arthus reaction and Forssman shock in guinea pigs. Studies in rats demonstrate CAB-2 to exhibit favorable biphasic pharmacokinetics with a t1/2 alpha of 10 min and a t1/2 beta of 8 h; the beta phase accounts for 93% of the administered dose. CAB-2 may be an effective therapeutic treatment of acute human diseases in which excessive complement activation causes damage to normal tissues. ------>tmu_sno=None ------>sno=7713 ------>authors2=None ------>authors3=None ------>authors4=None ------>authors5=None ------>authors6=None ------>authors6_c=None ------>authors=Higgins PJ, Ko JL, Lobell R, Sardonini C, Alessi MK, Yeh CG ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c=None ------>publish_area=None ------>updateTitle=A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities. ------>language=2 ------>check_flag= ------>submit_date= ------>country=None ------>no=6 ------>patent_SDate=None ------>update_bywho= ------>publish_year=1997 ------>submit_flag= ------>publish_month=None |